In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 1 to 10 of 105

Sort by

Keyword or reference number: cancer`Remove $Keyword or reference number: cancer filter`

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer [TSID12065]	Technology appraisal guidance	TBC
Advanced breast cancer: diagnosis and management (Partial update)	NICE guideline	5 June 2026
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]	Technology appraisal guidance	28 May 2026
Artificial intelligence (AI) technologies to assist histopathology for breast cancer diagnosis [ID6732]	Technology appraisal guidance	TBC
Artificial intelligence (AI) technologies to assist histopathology for prostate cancer diagnosis [ID6684]	Technology appraisal guidance	21 April 2027
Artificial intelligence (AI) technologies to help detect prostate cancer on MRI	Health technology evaluation	12 November 2026
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer [TSID10701]	Technology appraisal guidance	TBC
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894]	Technology appraisal guidance	TBC
Atezolizumab for adjuvant treatment of circulating tumour DNA-positive high-risk muscle-invasive bladder cancer after cystectomy [ID6515]	Technology appraisal guidance	TBC
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]	Technology appraisal guidance	TBC

Results per page

10
25
50
All